Preliminary data from QUILT 3.055: a phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with Checkpoint Inhibitors (CPI)
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
